A bill to allow sponsors of certain new drug applications to rely upon investigations conducted in certain foreign countries, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
Sponsor. Senator for Kentucky. Republican.
Last Updated: Sep 29, 2016
Length: 4 pages
Sep 29, 2016
114th Congress, 2015–2017
Died in a previous Congress
This bill was introduced on September 29, 2016, in a previous session of Congress, but was not enacted.
What stakeholders are saying
Sep 29, 2016
Bills and resolutions are referred to committees which debate the bill before possibly sending it on to the whole chamber.
S. 3466 (114th) was a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
This bill was introduced in the 114th Congress, which met from Jan 6, 2015 to Jan 3, 2017. Legislation not enacted by the end of a Congress is cleared from the books.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
Civic Impulse. (2018). S. 3466 — 114th Congress: Accelerating New Pharmaceutical Competition Act. Retrieved from https://www.govtrack.us/congress/bills/114/s3466
“S. 3466 — 114th Congress: Accelerating New Pharmaceutical Competition Act.” www.GovTrack.us. 2016. February 22, 2018 <https://www.govtrack.us/congress/bills/114/s3466>
|title=S. 3466 (114th)
|accessdate=February 22, 2018
|author=114th Congress (2016)
|date=September 29, 2016
|quote=Accelerating New Pharmaceutical Competition Act
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.